Role of trabectedin in the treatment of soft tissue sarcoma

OncoTargets and Therapy

Volumn 2, Issue , 2009, Pages 105-113

  Christinat, Alexandre ^a   Leyvraz, Serge ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Chemotherapy; DNA minor groove binder; Soft tissue sarcoma; Trabectedin

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; DOXORUBICIN; IFOSFAMIDE; IRINOTECAN; PACLITAXEL; SEROTONIN 3 ANTAGONIST; TRABECTEDIN;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BONE MARROW SUPPRESSION; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERBILIRUBINEMIA; INBORN ERROR OF METABOLISM; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER TOXICITY; MALIGNANT FIBROUS HISTIOCYTOMA; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; REVIEW; RHABDOMYOLYSIS; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; TRANSAMINITIS; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 77953395371     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med. 2005;353:701-711.
2. Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(Suppl 2):ii89-ii93.
3. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997;350:1647-1654.
4. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993;11:1269-1275.
5. Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007;25:3144-3150. (Pubitemid 47218064)
6. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995;13:1537-1545.
7. Serrone L, Zeuli M, Papaldo P, Nardoni C, Pacetti U, Cognetti F. Ifosfamide and epirubicin combination in untreated sarcomas: two treatment schedules. Onkologie. 2001;24:465-468. (Pubitemid 33033409)
8. Nielsen OS, Judson I, van Hoesel Q, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2000;36:61-67. (Pubitemid 30035345)
9. Le Cesne A, Antoine E, Spielmann M, et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol. 1995;13:1600-1608.
10. Cerny T, Leyvraz S, von Briel T, et al. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 1999;10:1087-1094.
11. O'Bryan RM, Luce JK, Talley RW, Gottlieb JA, Baker LH, Bonadonna G. Phase II evaluation of adriamycin in human neoplasia. Cancer. 1973;32:1-8.
12. Frustaci S, Buonadonna A, Galligioni E, et al. Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study. J Clin Oncol. 1997;15:1418-1426. (Pubitemid 27167374)
13. Maurel J, Fra J, Lopez-Pousa A, et al. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). Cancer. 2004;100:1498-1506. (Pubitemid 38366854)
14. Patel SR, Vadhan-Raj S, Burgess MA, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol. 1998;21:317-321. (Pubitemid 28280151)
15. Reichardt P, Tilgner J, Hohenberger P, Dorken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol. 1998;16:1438-1443. (Pubitemid 28175763)
16. Leyvraz S, Zweifel M, Jundt G, et al. Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Ann Oncol. 2006;17:646-651.
17. Judson I. Systemic therapy of soft tissue sarcoma: an improvement in outcome. Ann Oncol. 2004;15(Suppl 4):iv193-iv196. (Pubitemid 39585334)
18. Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000;18:2676-2684. (Pubitemid 30463549)
19. Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M. Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review. Cancer. 2008;112:1197-1205.
20. Fayette J, Penel N, Chevreau C, et al. Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma. Invest New Drugs. 2009. Jan 16. [Epub ahead of print].
21. Dirix LY, Van Oosterom AT. Soft tissue sarcoma in adults. Curr Opin Oncol. 1999;11:285-295.
22. Fayette J, Blay JY. Genetic predictors for drug resistance in soft tissue sarcoma: a review of publications in 2004. Curr Opin Oncol. 2005;17:370-375. (Pubitemid 40904425)
23. Fata F, O'Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86:2034-2037.
24. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20:2824-2831. (Pubitemid 34651511)
25. Cosetti M, Wexler LH, Calleja E, et al. Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol. 2002;24:101-105. (Pubitemid 34150548)
26. Riggi N, Cironi L, Suva ML, Stamenkovic I. Sarcomas: genetics, signalling, and cellular origins. Part 1: The fellowship of TET. J Pathol. 2007;213:4-20. (Pubitemid 47354561)
27. Suva ML, Cironi L, Riggi N, Stamenkovic I. Sarcomas: genetics, signalling, and cellular origins. Part 2: TET-independent fusion proteins and receptor tyrosine kinase mutations. J Pathol. 2007;213:117-130. (Pubitemid 47612234)
28. Molinski TF, Dalisay DS, Lievens SL, Saludes JP. Drug development from marine natural products. Nat Rev Drug Discov. 2009;8:69-85.
29. Martinez EJ, Corey EJ. A new, more efficient, and effective process for the synthesis of a key pentacyclic intermediate for production of ecteinascidin and phthalascidin antitumor agents. Org Lett. 2000;2:993-996.
30. Cuevas C, Perez M, Martin MJ, et al. Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B. Org Lett. 2000;2:2545-2548.
31. Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer. 2001;37:97-105. (Pubitemid 32119366)
32. Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem. 1999;42:2493-2497. (Pubitemid 29344290)
33. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med. 2001;7:961-966. (Pubitemid 32756435)
34. Soares DG, Escargueil AE, Poindessous V, et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A. 2007;104:13062-13067. (Pubitemid 351737593)
35. Gajate C, An F, Mollinedo F. Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis. J Biol Chem. 2002;277:41580-41589. (Pubitemid 35257462)
36. Izbicka E, Lawrence R, Raymond E, et al. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol. 1998;9:981-987. (Pubitemid 28496707)
37. Li WW, Takahashi N, Jhanwar S, et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res. 2001;7:2908-2911 (Pubitemid 32911401)
38. Valoti G, Nicoletti MI, Pellegrino A, et al. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res. 1998;4:1977-1983. (Pubitemid 28369184)
39. Hendriks HR, Fiebig HH, Giavazzi R, Langdon SP, Jimeno JM, Faircloth GT. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol. 1999;10:1233-1240. (Pubitemid 29533575)
40. Brandon EF, Meijerman I, Klijn JS, et al. In vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction. Anticancer Drugs. 2005;16:935-943. (Pubitemid 41416084)
41. van Kesteren C, Cvitkovic E, Taamma A, et al. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res. 2000;6:4725-4732. (Pubitemid 32110411)
42. Beumer JH, Rademaker-Lakhai JM, Rosing H, Lopez-Lazaro L, Beijnen JH, Schellens JH. Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer. Invest New Drugs. 2005;23:429-436. (Pubitemid 41160090)
43. Forouzeh B, Hidalgo M, Denis L, et al. Phase I and pharmacokinetic study of the marinederived DNA minor groove binder ET-743 on a weekly × 3 every-4-week schedule in patients with advanced solid malignancies. Proc Am Soc Clin Oncol. 2001;20: Abstract # 373.
44. Ryan DP, Supko JG, Eder JP, et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res. 2001;7:231-242. (Pubitemid 32183024)
45. Taamma A, Misset JL, Riofrio M, et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol. 2001;19:1256-1265. (Pubitemid 32202528)
46. Twelves C, Hoekman K, Bowman A, et al. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer. 2003;39:1842-1851. (Pubitemid 37311179)
47. Villalona-Calero MA, Eckhardt SG, Weiss G, et al. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily × 5 schedule in patients with solid malignancies. Clin Cancer Res. 2002;8:75-85. (Pubitemid 34101461)
48. Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004;22:890-899. (Pubitemid 41103601)
49. Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005;23:576-584 (Pubitemid 46224235)
50. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004;22:1480-1490. (Pubitemid 41103631)
51. Morgan JA, Le Cesne A, Chawla S, et al; Yondelis Sarcoma Study Group. Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracylines (A) and ifosfamide (I). J Clin Oncol. 2007;25(June 20 Supplement):18S, ASCO Annual Meeting Proceedings Part I Vol25, No 18S (June 20 Supplement), 10060.
52. Blay JY, Le Cesne A, Verweij J, et al. A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2004;40:1327-1331. (Pubitemid 38737018)
53. Le Cesne A, Misset JL, Demetri G, et al. Consistent evidence of activity of ecteinascidin (ET-743) in pretreated, advanced soft tissue sarcoma (ASTS): results from a pooled analysis of three pivotal phase II clinical trials (p2ct) and safety profile of a 24 h infusion schedule. European Journal of Cancer. 2001;37:S34-S.
54. D'Incalci M, Jimeno J. Preclinical and clinical results with the natural marine product ET-743. Expert Opin Investig Drugs. 2003;12:1843-1853. (Pubitemid 37408131)
55. Grosso F, Dileo P, Sanfilippo R, et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer. 2006;42:1484-1490 (Pubitemid 43903160)
56. Huygh G, Clement PM, Dumez H, et al. Ecteinascidin-743: evidence ofactivity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma. 2006;56282. (Pubitemid 46410545)
57. Grosso. Trabectedin in Soft Tissue Sarcomas (STS) carrying a chromosomal translocation: an exploratory analysis. Seattle, WA: 13th CTOS meeting, Nov 1-3, 2007. Abstract # 900 2007.
58. Dileo M. Final results of a phase II trial of 3-hr infusion trabectedin in patients with recurrent sarcomas. Istanbul, Turkey: 31st ESMO Congress Sept 29 - Oct 3, 2006. Abstract # 524P 2006.
59. Mohan V. Updated results of Phase II study of trabectedin (ET-743) in pretreated patients with advanced/ metastatic soft tissue sarcoma from a single institute. Chicago, IL: ASCO American Society of Clinical Oncology, 44th Annual Meeting, May 30 - Jun 3, 2008. Abstract # 21506 2008.
60. Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002;38:543-549. (Pubitemid 34185394)
61. Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol. 2005;23:5484-5492. (Pubitemid 46300141)
62. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007;8:595-602. (Pubitemid 46995623)
63. Donald S, Verschoyle RD, Greaves P, et al. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novelantitumor drug yondelis (ET-743) in the rat. Cancer Res. 2003;63:5902-5908. (Pubitemid 37187491)
64. Donald S, Verschoyle RD, Greaves P, Orr S, Jimeno J, Gescher AJ. Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes in vitro. Cancer Chemother Pharmacol. 2004;53:305-312. (Pubitemid 38392355)
65. Puchalski TA, Ryan DP, Garcia-Carbonero R, et al. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol. 2002;50:309-319.
66. Skorupa A, Beldner M, Kraft A, Montero AJ. Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma. Cancer Biol Ther. 2007;6(7):1015-1017. (Pubitemid 351574950)
67. Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res. 2002;62:3377-3381. (Pubitemid 34651382)
68. Jin S, Gorfajn B, Faircloth G, Scotto KW. Ecteinascidin-743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci U S A. 2000;97:6775-6779. (Pubitemid 30412790)
69. Minuzzo M, Ceribelli M, Pitarque-Marti M, et al. Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters. Mol Pharmacol. 2005;68:1496-1503. (Pubitemid 41540005)
70. Forni C, Minuzzo M, Virdis E, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009;8:449-457.
71. Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res. 2006;66:8155-8162. (Pubitemid 44299183)
72. Schöffski P. DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I Vol24, No 18S (June 20 Supplement), 2006:9522.
73. Meco D, Colombo T, Ubezio P, et al. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol. 2003;52:131-138. (Pubitemid 37041346)
74. Riccardi A, Meco D, Ubezio P, et al. Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft. Anticancer Drugs. 2005;16:811-815. (Pubitemid 41215745)
75. Takahashi N, Li WW, Banerjee D, Scotto KW, Bertino JR. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res. 2001;7:3251-3257 (Pubitemid 32963850)
76. Sessa C, Perotti A, Noberasco C, et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer. 2008 Dec 27. [Epub ahead of print].
77. von Mehren M, Schilder RJ, Cheng JD, et al. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol. 2008;19:1802-1809
78. Papadopoulos. Phase I and pharmacokinetics (PK) study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. J Clin Oncol. 2006; ASCO Annual Meeting Proceedings Part I, 2006;24:(June 20 Supplement)18S, 2029.
79. Gore L. Phase I combination study of trabectedin (T) and capecitabine (C) in patients with advanced malignancies. J Clin Oncol. 2006; ASCO Annual Meeting Proceedings Part I, 2006;24:(June 20 Supplement)18S, 2079.